JP2021523881A5 - - Google Patents
Info
- Publication number
- JP2021523881A5 JP2021523881A5 JP2020551266A JP2020551266A JP2021523881A5 JP 2021523881 A5 JP2021523881 A5 JP 2021523881A5 JP 2020551266 A JP2020551266 A JP 2020551266A JP 2020551266 A JP2020551266 A JP 2020551266A JP 2021523881 A5 JP2021523881 A5 JP 2021523881A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- binding fragment
- antibody
- dose
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862647928P | 2018-03-26 | 2018-03-26 | |
| US62/647,928 | 2018-03-26 | ||
| US201962811800P | 2019-02-28 | 2019-02-28 | |
| US62/811,800 | 2019-02-28 | ||
| PCT/IB2019/052408 WO2019186369A1 (en) | 2018-03-26 | 2019-03-25 | Methods of treating chronic spontaneous urticaria using ligelizumab |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021523881A JP2021523881A (ja) | 2021-09-09 |
| JP2021523881A5 true JP2021523881A5 (https=) | 2022-03-31 |
| JP7589045B2 JP7589045B2 (ja) | 2024-11-25 |
Family
ID=66476672
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020551266A Active JP7589045B2 (ja) | 2018-03-26 | 2019-03-25 | リゲリズマブを使用して慢性特発性蕁麻疹を治療する方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20210115155A1 (https=) |
| EP (1) | EP3773904A1 (https=) |
| JP (1) | JP7589045B2 (https=) |
| KR (1) | KR20200135826A (https=) |
| CN (1) | CN112203724A (https=) |
| AU (1) | AU2019244666A1 (https=) |
| CA (1) | CA3094749A1 (https=) |
| IL (1) | IL277474B2 (https=) |
| WO (1) | WO2019186369A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021250546A1 (en) | 2020-06-09 | 2021-12-16 | University Of Washington | Micrornas as predictors of response to anti-ige therapies in chronic spontaneous urticaria |
| WO2021250533A1 (en) * | 2020-06-09 | 2021-12-16 | Novartis Ag | Methods of treatment using omalizumab or ligelizumab |
| CN117460531A (zh) * | 2021-06-14 | 2024-01-26 | 诺华股份有限公司 | 含有抗IgE抗体的药物配制品 |
| CN117897409A (zh) * | 2021-08-13 | 2024-04-16 | 基因泰克公司 | 抗类胰蛋白酶抗体的给药 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0200429D0 (en) * | 2002-01-09 | 2002-02-27 | Novartis Ag | Organic compounds |
| WO2004070011A2 (en) | 2003-02-01 | 2004-08-19 | Tanox, Inc. | HIGH AFFINITY ANTI-HUMAN IgE ANTIBODIES |
| MXPA05010555A (es) * | 2003-04-04 | 2006-03-09 | Genentech Inc | Formulaciones de proteina y anticuerpo de alta concentracion. |
| CN102702359A (zh) * | 2004-02-02 | 2012-10-03 | 泰勒公司 | 新的IgE表位的鉴别 |
| CA2840731A1 (en) * | 2011-06-29 | 2013-01-03 | Allergan, Inc. | Alcaftadine for use in the treatment of urticaria |
| TW201343176A (zh) * | 2012-04-16 | 2013-11-01 | Novartis Ag | 使用ｉｌ－１７拮抗劑治療乾癬性關節炎之方法 |
| CN104547325A (zh) * | 2015-01-21 | 2015-04-29 | 李健 | 一种治疗慢性特发性荨麻疹的药物组合物及其应用 |
-
2019
- 2019-03-25 US US17/041,291 patent/US20210115155A1/en not_active Abandoned
- 2019-03-25 JP JP2020551266A patent/JP7589045B2/ja active Active
- 2019-03-25 CA CA3094749A patent/CA3094749A1/en active Pending
- 2019-03-25 EP EP19723202.8A patent/EP3773904A1/en active Pending
- 2019-03-25 CN CN201980021766.9A patent/CN112203724A/zh active Pending
- 2019-03-25 KR KR1020207030057A patent/KR20200135826A/ko not_active Ceased
- 2019-03-25 AU AU2019244666A patent/AU2019244666A1/en not_active Abandoned
- 2019-03-25 WO PCT/IB2019/052408 patent/WO2019186369A1/en not_active Ceased
- 2019-03-25 IL IL277474A patent/IL277474B2/en unknown
-
2023
- 2023-12-20 US US18/391,485 patent/US20250026858A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7544766B2 (ja) | 片頭痛の治療または予防法 | |
| JP7559112B2 (ja) | グルカゴン様ペプチド１受容体アゴニストおよびそれらの使用 | |
| JP7736667B2 (ja) | Ｉｌ－４ｒアンタゴニストを投与することによるアトピー性皮膚炎の治療方法 | |
| TWI755763B (zh) | 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法 | |
| TWI606840B (zh) | 具有增進高濃度之抗-ＴＮＦα抗體之液體調配物 | |
| JP6596014B2 (ja) | 爪および頭皮乾癬の治療方法 | |
| JP2017160208A5 (https=) | ||
| JP2021523881A5 (https=) | ||
| CN112153982A (zh) | 用于通过施用il-4r抑制剂治疗特应性皮炎的方法 | |
| TWI894144B (zh) | 藉由投予il-33拮抗劑治療或預防哮喘之方法 | |
| JP2022532927A5 (https=) | ||
| JP2022126791A (ja) | Ｉｌ－１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法 | |
| JP2019521156A5 (https=) | ||
| EP4612183A1 (en) | Methods for treating hand and foot dermatitis by administering an il-4r antagonist | |
| JP2024542777A5 (https=) | ||
| EP4440617A1 (en) | Interleukin 5 binding protein dosage regimen for use in treating polyangiitis, hypereosinophilic syndrome, hypereosinophilic syndrome chronic rhinosinusitis with nasal polyps (crswnp), or chronic rhinosinusitis without nasal polyps (crssnp) | |
| JP2025539702A (ja) | 肥満症を治療する方法 | |
| RU2020134794A (ru) | Способы лечения хронической спонтанной крапивницы с применением лигелизумаба | |
| JP2024500912A5 (https=) | ||
| TW202206457A (zh) | 用於治療呼吸疾病之泛elr+ cxc趨化因子抗體 | |
| RU2828020C2 (ru) | Способы лечения атопического дерматита посредством введения антагониста il-4r | |
| RU2024105814A (ru) | Лечение атопического дерматита | |
| RU2023102788A (ru) | Лечение гнойного гидраденита с использованием антагонистов il-17 | |
| CA3187136A1 (en) | Methods of treating thyroid eye disease and graves' orbitopahy using interleukin-17 (il-17) antagonists | |
| AU2020396455A1 (en) | Methods of treating lichen planus using Interleukin-17 (IL-17) antagonists |